shutterstock_1246881214_piotr_swat
Piotr Swat / Shutterstock.com
1 October 2020AmericasRory O'Neill

Celgene, Teva execs grilled over price hikes

A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
19 October 2020   Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office.
Americas
3 December 2020   Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
Americas
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

More on this story

Big Pharma
19 October 2020   Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office.
Americas
3 December 2020   Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
Americas
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

More on this story

Big Pharma
19 October 2020   Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office.
Americas
3 December 2020   Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
Americas
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.